ClinicalTrials.gg
RecruitingNCT06008925Updated Aug 24, 2023

Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

A Phase 1/2 interventional study of Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) and Nivolumab Injection in Metastatic Gastric Cancer, sponsored by CNBG-Virogin Biotech (Shanghai) Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-24.

Sponsored by CNBG-Virogin Biotech (Shanghai) Ltd. · Phase 1/2, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Nov 2022, registered Mar 2023).
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,187 studies in Stomach Neoplasms with a site in China — 483 open to participants now, 560 under way, 50 of them phase 3. Stomach Neoplasms · China.

Planned enrollment
628th of 884
43 · median 87
Started
2022
with 104 others
Phase 1/2
74 of 1,187
26 open now
Primary completion
2025-12
later than 179 of 559 live
Registered
700th of 1,187
by date

Among the 1,187 studies in Stomach Neoplasms with a site in China, this one is the 628th largest by planned enrollment of the 884 interventional ones that give a count, is one of 105 that started in 2022, is one of 74 in phase 1/2, reaches primary completion later than 179 of the 559 other live ones, and was the 700th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

483 of the 1,187 studies in Stomach Neoplasms with a site in China are open now. Recruiting first, the newest first:

478 more — sign in →

All 483 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,187 studies in Stomach Neoplasms with a site in China, or all of them as a file.
02

Study summary

VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 injection. This study will be conducted in combination with nivolumab injection in HSV seropositive subjects with advanced metastatic gastric or gastroesophageal junction adenocarcinoma who have previously received two or more systemic treatment regimens (which must include anti-PD-1 monoclonal antibodies). This is an open-label study divided into two parts.

Part 1: This part is an escalating dose trial to explore the safety of the combination and determine the recommended safe dose of the combination.

Part 2: This part is an extension trial to investigate the preliminary efficacy of the combination at a safe dose.

Read the detailed description

Part1(Phase Ib primary objective): To evaluate the safety and tolerability of VG161 administered by intratumoral injection combined with Nivolumab Injection in the treatment of patients with advanced metastatic gastric or gastroesophageal junction adenocarcinoma who have previously received two or more systemic treatment regimens (including anti-PD-1 monoclonal antibodies), explore the most suitable recommended Phase II dose (RP2D) for combination therapy, and determine the recommended regimen for combination therapy in Phase IIa clinical trials. Secondary objectives: 1) To preliminarily evaluate the antitumor activity of VG161 combined with nivolumab injection in the treatment of patients with advanced gastric cancer; 2) To monitor the changes of immunological parameters related to pharmacodynamics; 3) To evaluate the relevant immunological characteristics of tumor biopsy samples; 4) To evaluate the pharmacokinetic (PK) characteristics and viral excretion of single and multiple intratumoral injections of VG161;

Part2(Phase IIa Primary Objective): To further evaluate the safety and efficacy of intratumoral injection of VG161 combined with nivolumab injection in patients with advanced metastatic gastric or gastroesophageal junction adenocarcinoma who have previously received two or more systemic treatment regimens (which must include anti-PD-1 monoclonal antibodies), with the primary outcome measure of efficacy being objective response rate (ORR). Secondary objectives: 1) To evaluate the secondary outcome measures of the efficacy of combined treatment; 2) To monitor the pharmacodynamic-related changes in immunological parameters; 3) To evaluate the relevant immunological characteristics of tumor biopsy samples;

03

Conditions studied

  • Metastatic Gastric Cancer

Browse trials for

Keywords

  • Gastric cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (Subjects must meet all of the following inclusion criteria to enter the trial)
  1. Subjects must give to this study before the trial and voluntarily sign a written informed consent form.
  2. aged 18 to 75 years (inclusive), male or female.
  3. Patients with advanced gastric or gastroesophageal junction adenocarcinoma confirmed by histopathology or cytology.
  4. According to the Guidelines for the Diagnosis and Treatment of Gastric Cancer (CSCO, version 2021), patients must have previously failed two or more systemic treatment regimens (which must include monoclonal antibodies), or patients who cannot continue treatment due to severe adverse reactions as judged by the investigator.
  5. Be able to provide paraffin blocks and/or tissue sections of previously archived pathological tissues, or willing to undergo tumor tissue before administration.
  6. The presence of at least one measurable CT scan according to 1.1 and meeting the requirements for an acceptable injection dose volume (or the first injection dose volume in Phase IIa) in the current dose group, tumor metastases that can be injected under ultrasound guidance (injected lesions are best major tumor burden lesions), and the baseline longest diameter of the injected lesion (lymph node lesions are short diameters) > 1.5 cm.
  7. Positive test result for herpes simplex virus I antibodies (HSV-1 IgG or HSV-1 IgM).
  8. performance status score 0-1.
  9. Expected survival time of more than 3 months.
  10. adequate organ function: 1) blood routine (no blood transfusion or colony-stimulating factor treatment within 14 days): ≥ 1.5 × 10\^9/L, ≥ 100 × 10\^9/L, ≥ 85 g/L, lymphocyte count ≥ 1.5 × 10\^9/L (for lymphocyte count 0.8 × 10\^9/L to 1.5 × 10\^9/L, the investigator judged whether to enroll); 2) liver function: ≤ 1.5 × , ≤ 3 × ULN, AST ≤ 3 × ULN; 3) renal function: Cr ≤ 1.5 × ULN, and ≥ 45ml/min (calculated according to Cockcroft-Gault formula); 4) coagulation function: (APTT) ≤ 1.5 × ULN, international normalized ratio (INR) ≤ 1.5 × ULN.
  11. eligible subjects of (men and women) must agree to use a reliable method of (hormonal or barrier method or abstinence) during the trial and for at least 90 days after the last dose (VG161 or nivolumab, calculated at the later of the day).
  12. Female patients of childbearing age must have a negative blood pregnancy test within 1 day prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  • (Any of the following criteria must be excluded)
  1. received chemotherapy, radiotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy and other anti-tumor drugs within 4 weeks before the first use of the study drug, of which oral fluorouracil and small molecule targeted drugs were within 2 weeks before the first use of the study drug or within 5 half-lives of the drug (whichever was longer).
  2. received other unmarketed clinical trial treatment within 4 weeks before the first dose of study drug.
  3. Major organ surgery (excluding needle ) or significant trauma within 4 weeks before the first dose of study drug.
  4. Patients who have received systemic (prednisone > 10 mg/day or equivalent doses of the same class of drugs) or other agents within 14 days before the first dose of study drug; except for the following: topical, ocular, intra-articular, intranasal, and inhaled corticosteroids; short-term corticosteroids (≤ 10 mg prednisone equivalent) for prophylaxis (e.g., prevention of contrast agent allergy).
  5. Vaccination within 4 weeks prior to the first dose of study drug.
  6. Adverse reactions of previous anti-tumor treatment have not recovered to 5.0 grade evaluation ≤ 1 (except alopecia and other toxicities judged by the investigator as having no safety risk).
  7. Patients with central nervous system , spinal cord metastasis and/or spinal cord compression.
  8. patients with active diverticulitis or symptomatic gastrointestinal ulcers;
  9. in the herpes simplex virus recurrence infection period, and there are corresponding clinical manifestations, such as oral herpes labialis, herpes keratitis herpeticum, genital herpes, etc., or there are herpes infection-related complications (herpes keratitis, encephalitis, nerve injury, etc.), and intermittent or long-term use of anti-herpes drugs (e.g., acyclovir) treatment, except intermittent local use.
  10. other active uncontrolled infections.
  11. History of immunodeficiency, including positive antibody test and positive Treponema pallidum antibody test.
  12. Patients with active chronic or active (except hepatitis B virus carriers, stable hepatitis B after drug treatment [HBV-DNA test negative or \< 50 IU/ml] and cured hepatitis C patients [HCV RNA test negative]);
  13. history of serious cardiovascular disease: 1) ventricular arrhythmia requiring clinical intervention; 2) > 480 ms; 3) Acute coronary syndrome, congestive heart failure, stroke or other Grade III or higher cardiovascular events within 6 months; 4) (NYHA) functional classification ≥ II or (LVEF) \< 40%; 5) uncontrolled hypertension after treatment (as judged by the investigator).
  14. Patients with active, or have had and have had diseases that may recur (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes, etc.); but excluding patients with clinically stable autoimmune thyroiditis, autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormone; type I diabetes using stable doses of insulin; vitiligo or recovered childhood asthma/allergy, and patients who do not require any intervention in adulthood.
  15. Having received immunotherapy and have experienced immune-related adverse events (irAEs) such as immune-related pneumonia and myocarditis, which may affect the safety of the drug as judged by the investigator.
  16. Patients who have received and develop serious adverse reactions after treatment and need to be permanently disabled.
  17. Known alcohol or drug dependence.
  18. Mental disorders or poor compliance.
  19. Pregnant or lactating women.
  20. subjects with pleural effusion or pericardial effusion or ascites requiring clinical intervention.
  21. The investigator believes that the subject has other serious systemic diseases or other reasons and is not suitable for this clinical study.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (estimated)

Study arms

  • Experimental
    Single Arm

    Part1: VG161: 1) 1.0 × 10 \^ 8 PFU daily on Day 1 of each cycle (D1); 2)1.0 × 10 \^ 8 PFU daily for 2 consecutive days on Days 1-2 of each cycle (D1-D2); 3)1.0 × 10 \^ 8 PFU daily for 3 consecutive days on days 1-3 (D1-D3) in the first cycle; 1.0 × 10 \^ 8 PFU daily for 2 consecutive days on days 1-2 (D1-D2) in the second and subsequent cycles; Nivolumab Injection: 3 mg/kg every 2 weeks (D8, D22) Part2: Depends on the recommended dose in Part1

    Drug: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) · Drug: Nivolumab Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Phase Ib:RP2D/MTD

    RP2D/MTD for VG161 in Combination with Nivolumab

    Time frame: through Phase Ib study completion, an average of 1 year

  2. Phase Ib:Incidence and number of DLT

    Incidence and number of DLT (dose-limiting toxicity)

    Time frame: through Phase Ib study completion, an average of 1 year

  3. Phase Ib and Phase IIa:AE, SAE occurrence and frequency

    Occurrence and frequency of AE (Adverse Event) and SAE(Serious adverse event)

    Time frame: through Phase Ib and Phase IIa study completion, an average of 2 year

  4. Phase IIa:ORR

    Objective response rate (ORR)

    Time frame: through Phase IIa study completion, an average of 1 year

Secondary outcomes

  1. Phase Ib and Phase IIa:ORR and DCR

    Objective response rate (ORR) and disease control rate (DCR)

    Time frame: through Phase Ib and Phase IIa study completion, an average of 2 year

  2. Phase Ib and Phase IIa:PFSand OS

    Progression Free Survival (PFS) and Overall Survival (OS)

    Time frame: through Phase Ib and Phase IIa study completion, an average of 2 year

  3. Phase Ib and Phase IIa:DOR

    Duration of Response (DOR)

    Time frame: through Phase Ib and Phase IIa study completion, an average of 2 year

  4. Phase Ib and Phase IIa: Immunological indicators

    Immunological parameters: peripheral blood lymphocyte subsets (CD3 +, CD4 +, CD8 +, CD4 +/CD8 + ratio, CD19 +, CD16 + CD56 + (NK) cells), cytokines (IL-12, IL-15, IL-6, TNF-α, IFN-γ);

    Time frame: through Phase Ib and Phase IIa study completion, an average of 2 year

  5. Phase Ib and Phase IIa:Correlation of PD-L1 combined positive score (CPS) with safety and efficacy

    Correlation of PD-L1 combined positive score (CPS) with safety and efficacy

    Time frame: through Phase Ib and Phase IIa study completion, an average of 2 year

  6. Phase Ib and Phase IIa:Correlation of herpes simplex virus type I antibodies with safety and efficacy

    Correlation of herpes simplex virus type I antibodies with safety and efficacy

    Time frame: through Phase Ib and Phase IIa study completion, an average of 2 year

  7. Phase Ib and Phase IIa:Immunohistochemical detection of HER2、CD68、 CD3、 CD4、 CD8、CD47

    Immunohistochemical detection of HER2、CD68、 CD3、 CD4、 CD8、CD47

    Time frame: through Phase Ib and Phase IIa study completion, an average of 2 year

  8. Phase Ib :Pharmacokinetic parameters: Blood concentrations of VG161 at different time points after single and multiple doses

    Pharmacokinetic parameters: Blood concentrations of VG161 at different time points after single and multiple doses

    Time frame: through Phase Ib study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Dec 2025, 37 months after the start.

Of 91 industry-sponsored phase 1/2 interventional studies under Stomach Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 109. This study's planned 37 months is below that.

Counting every sponsor, half of 158 studies reached it within 60 months; a quarter within 40 and three quarters within 109.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2023
First posted
Aug 24, 2023
StartActual
Nov 17, 2022
Primary completionEst.
Dec 2025
CompletionEst.
Jun 2026
Last update
Aug 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06008925
Lead sponsor
CNBG-Virogin Biotech (Shanghai) Ltd.
Responsible party
Sponsor
First posted
Aug 24, 2023
Start date
Nov 17, 2022
Primary completion
Dec 2025 (estimated)
Completion
Jun 2026 (estimated)
Last update
Aug 24, 2023

Study contacts

Lin Shen, Professor
Contact
doctorshenlin@sina.cn
13911219511 ext. 010-88196561
Lin Shen
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oncolytic HSV-1 Expressing IL-12, IL-15/IL-15-receptor Alpha and PD-L1 Blocking Peptide VG161

Start the discussion